electroCore, Inc. $ECOR Shares Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its holdings in shares of electroCore, Inc. (NASDAQ:ECOR) by 65.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 77,020 shares of the company’s stock after purchasing an additional 30,550 shares during the period. International Assets Investment Management LLC’s holdings in electroCore were worth $407,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of ECOR. AWM Investment Company Inc. grew its position in electroCore by 95.0% during the 1st quarter. AWM Investment Company Inc. now owns 318,106 shares of the company’s stock worth $2,128,000 after purchasing an additional 154,973 shares during the last quarter. NewEdge Advisors LLC grew its position in electroCore by 857.9% during the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after purchasing an additional 145,047 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in electroCore during the 1st quarter worth $153,000. Jane Street Group LLC grew its position in electroCore by 114.4% during the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after purchasing an additional 19,599 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in electroCore during the 1st quarter worth $95,000. 26.74% of the stock is owned by hedge funds and other institutional investors.

electroCore Trading Down 2.8%

ECOR stock opened at $4.83 on Thursday. The company has a market cap of $38.64 million, a P/E ratio of -2.98 and a beta of 0.34. The company’s 50-day moving average price is $5.08 and its 200 day moving average price is $5.67. electroCore, Inc. has a 52 week low of $4.16 and a 52 week high of $19.49.

electroCore (NASDAQ:ECOR) last announced its earnings results on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $7.38 million for the quarter, compared to analyst estimates of $7.24 million. electroCore had a negative return on equity of 221.93% and a negative net margin of 47.84%. On average, equities research analysts expect that electroCore, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on ECOR shares. Wall Street Zen downgraded shares of electroCore from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of electroCore in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, electroCore currently has an average rating of “Hold” and an average price target of $25.50.

Insider Transactions at electroCore

In other electroCore news, Director Thomas J. Errico bought 15,000 shares of the business’s stock in a transaction on Monday, August 11th. The stock was bought at an average price of $4.47 per share, for a total transaction of $67,050.00. Following the completion of the transaction, the director owned 281,401 shares in the company, valued at approximately $1,257,862.47. The trade was a 5.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.80% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.